Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DE:4DN)
FRANKFURT:4DN
Denali Therapeutics (4DN) Ownership Overview
9.16% Insiders
33.39% Mutual Funds
30.59% Other Institutional Investors
15.44% ETFs
11.42% Public Companies and Individual Investors
The ownership structure of Denali Therapeutics (DE:4DN) stock is a mix of institutional, retail, and individual investors. Approximately 79.43% of the company’s stock is owned by Institutional Investors, 9.16% is owned by Insiders, and 11.42% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jan 08, 2025 | Steve E. Krognes Director | xxxxxxxxxxxxx | $69485 |
| Jan 08, 2025 | Carole Ho Cmo | xxxxxxxxxxxxx | $308291 |
| Jan 08, 2025 | Ryan J. Watts President & Ceo,director | xxxxxxxxxxxxx | $750955 |
| Jan 08, 2025 | Alexander O. Schuth Cofo And Secretary | xxxxxxxxxxxxx | $308291 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $421988 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $2038000 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $16151129 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 11,359,163 | Institution | 7.89% | 241,757,066 | |
| 9,358,249 | Institution | 6.50% | 199,171,613 | |
| 8,797,384 | Institution | 6.11% | 187,234,724 | |
| 6,211,925 | Institution | 4.32% | 132,208,400 | |
| 5,750,882 | Insider | 4.20% | 122,396,022 | |
| 5,978,373 | Institution | 4.15% | 127,237,713 | |
| 3,795,618 | Institution | 2.64% | 80,782,138 | |
| 3,731,695 | Institution | 2.59% | 79,421,665 | |
| 2,455,675 | Insider | 1.71% | 52,264,131 | |
| 2,117,408 | Insider | 1.47% | 45,064,794 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,358,249 | Institution | 6.50% | 199,171,613 | |
| 8,797,384 | Institution | 6.11% | 187,234,724 | |
| 5,978,373 | Institution | 4.15% | 127,237,713 | |
| 3,795,618 | Institution | 2.64% | 80,782,138 | |
| 2,041,163 | Institution | 1.42% | 43,442,072 | |
| 1,638,780 | Institution | 1.14% | 34,878,155 | |
| 1,382,410 | Institution | 0.96% | 29,421,832 | |
| 1,251,766 | Institution | 0.87% | 26,641,336 | |
| 1,064,733 | Institution | 0.74% | 22,660,712 | |
| 1,031,060 | Institution | 0.72% | 21,944,050 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Denali Therapeutics (DE:4DN)?
According to the latest TipRanks data, approximately 30.59% of the company's stock is held by institutional investors, 9.16% is held by insiders, and 11.42% is held by retail investors.
What percentage of Denali Therapeutics (DE:4DN) stock is held by institutional investors?
According to the latest TipRanks data, approximately 30.59% of Denali Therapeutics (DE:4DN) stock is held by institutional investors.
What percentage of Denali Therapeutics (DE:4DN) stock is held by retail investors?
According to the latest TipRanks data, approximately 11.42% of Denali Therapeutics (DE:4DN) stock is held by retail investors.
Who owns the most shares of Denali Therapeutics (DE:4DN)?
Vanguard owns the most shares of Denali Therapeutics (DE:4DN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.